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As the COVID-19 pandemic spreads across the globe, major
transformations are rapidly being implemented because of
the unprecedented pressure on health care systems. Manage-
ment of patients with cancer has been particularly affected
by the reduced access to cancer treatments related to pro-
longed wait times for diagnostic and interventional proce-
dures, treatment delays or interruptions, fragmentation of
multidisciplinary management with a shrinking oncology work-
force, and self-isolation for fear of nosocomial infection. Con-
sequently, there is a risk of detrimental consequences for this
highly vulnerable patient population. This dire scenario repre-
sents an opportunity to evaluate current practices and provide
a lesson for the future in the post–COVID-19 era. The case of
stereotactic body radiotherapy (SBRT) in hepatocellular carci-
noma (HCC) is emblematic.
SBRT has emerged as a noninvasive, painless, and effec-
tive therapeutic modality delivered in a few daily fractions
over less than 1 week for patients with HCC, from early to
advanced stage.
In early stage HCC, local therapy can be offered as a defini-
tive or bridging treatment [1]. Because of current restrictions
in access to operating rooms and the redeployment of anes-
thesiologists to intensive care units, SBRT represents an appeal-
ing option compared with invasive local therapies such as
surgery, radiofrequency or microwave ablation, and regional
therapies such as transarterial or radioembolization, which
may require general anesthesia and recovery. Although ran-
domized trials are lacking, indirect comparisons suggest compa-
rable efficacy of SBRT with these treatment modalities for
similar stage patients [2–4]. The use of SBRT may reduce the
need for systemic therapy in advanced patients with symptom-
atic involvement or poor responders to standard treatment,
e.g., macroscopic vascular invasion [5].
Despite the numerous studies demonstrating efficacy,
long-term survival, and low toxicity rates [6–8], many
current HCC treatment algorithms do not incorporate SBRT
in the management of HCC. Most limit its use to patients
who are ineligible for or refractory to other invasive local
and/or regional therapies. The significant time and effort
required, coupled with the limited funding and lack of phar-
maceutical and vendor support, have been an impediment
to conducting large-scale, potentially practice-changing clinical
trials of SBRT for HCC: thus, SBRT may be indefinitely
relegated to an ancillary role.
It is expected that, during the COVID-19 pandemic and
its aftermath, SBRT will increasingly represent a preferred
treatment that may relieve the burden of interrupted and
deferred cancer treatments, the overload of chemotherapy
facilities, and patient exposure and risk of COVID-19 infec-
tion because of repeated visits and prolonged stays in the
hospital [9]. With more widespread clinical use of SBRT,
there may be an increase in support for trials of this effec-
tive HCC treatment. It is crucial that outcome and toxicity
data be recorded during this time when nonstandard therapies
are offered. These data will hopefully provide further evidence
to reconsider SBRT as a first-line treatment option for HCC
(proposed algorithm is shown in Fig. 1).
It is our hope that the cumulative global experience
gained during the COVID-19 pandemic may allow for a full
recognition of SBRT as a useful therapy in the management
of HCC based on real-life evidence.
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Figure 1. Proposal for a modified Barcelona Clinic Liver Cancer staging system (BCLC)-based treatment algorithm during the COVID-
19 pandemic.
Abbreviations: HCC, hepatocellular carcinoma; PS, performance status; SBRT, stereotactic body radiotherapy.
© AlphaMed Press 2020
SBRT for HCC in the COVID-19 Era and Beyonde1250
